CD19 and diffuse large B-cell lymphoma: Tafasitamab, the first in kind humanized anti-CD19 mAb, with enhanced Fc portion to enable improved ADCC and ADCP, showed high response rates in combination with lenalidomide in the L-MIND study leading to the approval of this combination in patients with relapsed or refractory DLBCL ineligible for autologous transplant[24].